As clinical research, serum VEGF and FGF concentrations were measured in 57 RCC patients using the sandwich enzyme immunoassay. These factors showed no significant correlation with tumor size, TNM stage, subsequent recurrence or disease progression. However, a significantly high VEGF level was observed in V(+) patients compared to V(-) patients. Moreover, a significantly high FGF level was observed in pathologically low-grade patients compared to high-grade patients. As basic research, we constructed an adenovirus vector encoding a soluble VEGF receptor/flt-1 (Adflt-ExR). This soluble receptor is secreted from Adflt-ExR-transfected cells. Murine renal cell carcinoma cell line, Renca cells (5 × 105 cells) or murine bladder carcinoma cell line, MBT2 cells (2.5 × 105 cells) were infected by Adflt-ExR beforehand (at a multiplicity of infection [MOI] of 100) and injected subcutaneously into Balb/c or C3H/He mice, respectively. An adenovirus vector bearing the LacZ gene (AdLacZ) was used as a control. The growth of AdLacZ-infected Renca cells was observed in 5 out of 5 mice, While the growth of Adflt-ExR-infected Renca cells was observed in 3 out of 5 mice. Moreover, the growth of Adflt-ExR-infected MBT2 cells was significantly lower than that of AdLacZ-infected MBT2 controls (P<0.05). Adenovirus-mediated gene transfer of a soluble form of the VEGF receptor (flt-1) gene may be useful as an antiangiogenic therapy for urogenital cancer.
|ジャーナル||Nishinihon Journal of Urology|
|出版ステータス||出版済み - 2001|
All Science Journal Classification (ASJC) codes